Shares of boohoo Group PLC, now Debenhams Group, held steady after its half-year update. Broker Shore Capital maintained a 'buy' rating and raised its price target to 35p, suggesting nearly 50% upside from the current 24p. The broker highlighted accelerating sales, improved gross margins, and growth in the marketplace model as signs of recovery progress. Recent asset sales, including a £90 million warehouse and the Nasty Gal brand, support a shift to a capital-light model, improving profit forecasts and turning net debt into net cash. However, Shore Capital cautioned that the clothing market remains challenging in the near term, and long-term growth depends on boohoo's ability to sustain momentum across the group.
Shares of boohoo Group PLC, now Debenhams Group, provide context for consumer cyclical stocks. For readers following this sector, here is Pluang's market snapshot as of Sep 17, 2026 23:41 WIB: out of 105 US consumer cyclical stocks, 70 rose and 35 fell. Tesla (TSLA) traded at USD 367.65 with a 1-day change of +2.67%, while Gap (GAP) and Target (TGT) both saw 100% buy order activity with prices of USD 20.70 and USD 158.71 respectively.
Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
LlamaLend V2 strategy using 20x leverage on syrupUSDC reported a 37.1% yield, while another pool pairing sUSG with reUSD showed a 13.4% yield. The platform isolates lending markets with separate price feeds and borrowing caps, allowing supported Curv...
Solayer Pay has expanded its card app to accept stablecoin deposits directly from five blockchain networks: Solana, Ethereum, Arbitrum, BNB Chain, and Base. This update simplifies the process for users to fund their cards using stablecoins across mul...
Vertex Pharmaceuticals presented updates on its kidney disease research and development programs at the American Society of Nephrology (ASN) Kidney Week 2026. The event featured discussions on their portfolio, including new data on the AMKD program w...
